高危冒烟型骨髓瘤的治愈性策略:卡非佐米、来那度胺和地塞米松(KRd)序贯移植、KRd巩固和Rd维持
本研究纳入90例高危冒烟型骨髓瘤且适合移植的患者,接受KRd诱导6周期、大剂量美法仑(200 mg/m2)自体干细胞移植、2周期KRd巩固及2年Rd维持。移植后3个月意向治疗人群uMRD率为62%(56/90),移植后4年持续uMRD率为31%(29例)。中位随访70.1个月,70个月进展率94%(95% CI 84-89),总生存率92%(95% CI 82-89)。
要点
- 高危冒烟型骨髓瘤患者接受KRd序贯移植及维持治疗,移植后3个月uMRD率62%,4年持续uMRD率31%。
- 中位随访70.1个月,5例进展为多发性骨髓瘤,70个月进展率94%,总生存率92%。
- 中性粒细胞减少和感染是最常见不良事件,发生1例治疗相关死亡,报告3例第二原发恶性肿瘤。
核心结论
- 尽管需要更长时间随访,该治愈性方法令人鼓舞,且比活动性多发性骨髓瘤更有效,31%的患者在大剂量美法仑自体干细胞移植后4年维持uMRD。
研究设计与样本
- 前瞻性试验,纳入高危冒烟型骨髓瘤(2年进展风险>50%)且适合移植的患者,接受KRd诱导6周期、大剂量美法仑(200 mg/m2)自体干细胞移植、2周期KRd巩固及2年Rd维持。
- 主要终点为自体干细胞移植后下一代流式细胞术检测的uMRD率,次要终点为移植后4年持续uMRD。
- 2015年6月至2017年6月共纳入90例患者,31%符合至少一项SLiM-CRAB标准。
主要发现
- 中位随访70.1个月,移植后3个月意向治疗人群中56/90例(62%)达到uMRD,4年后29例(31%)维持uMRD。
- 5例进展为多发性骨髓瘤,70个月进展率94%(95% CI 84-89)。
- 存在任何SLiM-CRAB标准可预测进展为多发性骨髓瘤(5例中4例;HR 0.12;95% CI 0.14-1.13;P=0.03)。
- 36例出现生化进展,治疗结束时未达到uMRD可预测生化进展。
- 70个月总生存率92%(95% CI 82-89)。
关键数值与推荐
- 中性粒细胞减少和感染是治疗期间最常见的不良事件,导致1例治疗相关死亡。
- 报告3例第二原发恶性肿瘤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更长时间随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Early treatment of high-risk smoldering myeloma has been shown to delay progression to multiple myeloma (MM). We conducted this trial with curative intention using a treatment approach employed for newly diagnosed patients with MM. METHODS: Patients with high-risk smoldering myeloma (>50% progression risk at 2 years) and transplant candidates were included and received induction therapy with carfilzomib, lenalidomide, and dexamethasone (KRd), six cycles, followed by high-dose melphalan (200 mg/m2) autologous stem-cell transplantation (HDM-ASCT), two KRd consolidation cycles, and Rd maintenance for 2 years. The primary end point was undetectable measurable residual disease (uMRD) rate by next-generation flow after ASCT. Sustained uMRD 4 years after ASCT was the secondary end point. RESULTS: Between June 2015 and June 2017, 90 patients were included, and 31% met at least one SixtyLightchain MRI (SLiM)-hypercalcemia, renal impairment, anemia, bone disease (CRAB) criterion. After a median follow-up of 70.1 months, 3 months after ASCT, in the intention-to-treat population, 56 (62%) of 90 patients had uMRD, and 4 years later, it was sustained in 29 patients (31%). Five patients progressed to MM, and the 70-month progression rate was 94% (95% CI, 84 to 89). The presence of any SLiM CRAB criteria predicted progression to MM (four of the five patients; hazard ratio, 0.12; 95% CI, 0.14 to 1.13; P = .03). Thirty-six patients showed biochemical progression, and failure to achieve uMRD at the end of treatment predicted it. The 70-month overall survival was 92% (95% CI, 82 to 89). Neutropenia and infections were the most frequent adverse events during treatment, resulting in one treatment-related death. Three second primary malignancies have been reported. CONCLUSION: Although a longer follow-up is needed, this curative approach is encouraging and more effective than active MM, with 31% of the patients maintaining the uMRD 4 years after HDM-ASCT.
引用
- Mateos MV, Martínez-López J, Rodriguez Otero P, et al. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance. J Clin Oncol. 2024. PMID: 39038268. doi:10.1200/JCO.23.02771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。